CRISPR Appoints Tony Coles, M.D., To Its Board Of Directors
BASEL, Switzerland--(BUSINESS WIRE)--CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, today announced the appointment of Tony Coles, M.D., to the company’s Board of Directors.
“Dr. Coles is a venerated leader in the biotech industry with a strong track record of success,” said Rodger Novak, M.D., Chief Executive Officer of CRISPR Therapeutics.
“Dr. Coles is a venerated leader in the biotech industry with a strong track record of success,” said Rodger Novak, M.D., Chief Executive Officer of CRISPR Therapeutics.